Prosecution Insights
Last updated: November 12, 2026
Application No. 18/920,707

FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS

Non-Final OA §103§DOUBLEPATENT
Filed
Oct 18, 2024
Priority
Jul 21, 2016 — provisional 62/365,037 +3 more
Examiner
KOSTURKO, GEORGE W
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bodor Laboratories Inc.
OA Round
1 (Non-Final)
55%
Grant Probability
Moderate
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allowance Rate
402 granted / 736 resolved
-5.4% vs TC avg
Strong +49% interview lift
Without
With
+48.9%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
36 currently pending
Career history
779
Total Applications
across all art units

Office Action

§103 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-26 filed October 18, 2024 are currently pending. Priority Acknowledgement is made of the continuation of Application 17479905 now U.S. Patent 12,156,865. Application 17479904 is a continuation of Application 16319793, now U.S. Patent 11,123,325. Application 16319793 is a national stage entry of PCT/US2017/043106 filed 07/20/2017 which claims priority to U.S. Provisional Application 62365037 filed 07/21/2016. Information Disclosure Statement The information disclosure statement (IDS) submitted on 10/18/2024, 04/04/2025, 08/26/2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-15, 19-23 are rejected under 35 U.S.C. 103 as being unpatentable over the combination of Whipple (US Patent 6,319,491 published 11/20/2001) Bodor et al (US2014/0275204 published 09/18/2014), Bodor (US Patent 7,399,861 published 07/15/2008, referred to as Bodor ‘861) and Kawasaki (JP2003-113392 published 04/18/2003). Whipple teaches anti-sweat lotion designed for people suffering from hyperhidrosis. Said lotion comprises denatured ethyl alcohol, fumed silica treated with a polydimethylsiloxane polymer, a copolymer of methyl vinyl ether and maleic anhydride, decamethylcyclopentasiloxane (cyclomethicone) and hydroxypropyl cellulose (abstract). Whipple teaches that subjects with hyperhidrosis comprise uncontrolled sweating and find it difficult to interact socially, such as shaking hands with a wet clammy handshake (col. 1 lines 30-50). Whipple teaches that the anti-sweat lotion penetrates the skins surface, causing invisible barrier, which keeps sweat from forming on the skin’s surface, keeping it dry and comfortable for hours (col 2. Lines 10-15). All the ingredients are FDA approved, so it can be used safely and with confidence. Whipple teaches that the anti-sweat lotion is composed of 90% wt. denatured ethyl alcohol. Whipple teaches high levels of ethanol promote quick drying after application and have good levels of antiperspirant activity (col 1 lines 25-30; col. 3 lines 1-15). Whipple teaches that ethanol is 200 proof and is called SD-40-2, and comprises t-butyl alcohol and brucine sulfate (col. 3 lines 1-15). As evidenced by the MSDS of said SD-40-2, the composition is 99.86% ethanol 200 proof and 0.14% tert-butyl alcohol and brucine sulfate. As the ethanol does not contain water, the examiner has interpreted the denatured ethanol of Whipple as anhydrous ethanol. In addition, considering the anhydrous denatured ethyl alcohol comprises 90% wt. of the anti-sweat lotion, the examiner has interpreted that said 90% wt. anhydrous ethanol is present in an amount sufficient to act as a non-aqueous solvent. Regarding the viscosity controlling agent/gelling agent, Whipple teaches hydroxypropyl cellulose as a preferred film-forming and thickening component to be combined into the ethanol solution (col 4 lines 35-65). Additionally, Whipple teaches that decamethyl cyclopentasiloxane (cyclomethicone 5) is a suitable additive to use in the anti-sweat lotion (col. 4 lines 30-35). Whipple teaches treating hyperhidrosis in a subject comprising administering the disclosed anti-sweat lotion to the hands of a subject in need (col. 2 lines 10-20). However, Whipple does not teach the compound of Formula (Ia) in the anti-sweat lotion, in at least 1-25% wt. of the anti-sweat lotion. Additionally, Whipple does not specifically teach wherein the anti-sweat lotion comprises isopropyl myristate, nor citric acid, nor hexylene glycol. Bodor teaches compounds of Formula (Ia), including the elected (2R, 3’R)3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methyl-pyrrolidinium bromide) as a potent compound for treating hyperhidrosis (referred to as compound #5 [0057], claims 9, 15). Regarding claims 1-4, the anion of compound #5 is bromide. A preferred embodiment is formulating said compound as a 5% wt. solution in 70% ethanol ([0027]). Gels, lotions and creams wherein ethanol as the only solvent are also embodied in the teaching of Bodor ([0071], [0074-0076], claims 9-12). Bodor further teaches that said anti-sweat compounds may be combined with other active substances that treat perspiration ([0071]). Bodor teaches incorporating pH adjusting agents to the anti-sweat composition in order to keep the composition in a preferred pH range near 6 ([0073]). Bodor teaches treating hyperhidrosis in a subject in need comprising administering said composition to areas of the skin that are in need of sweat reduction, such as hand-palm areas, which reads on the methodology of claims 20-23 ([0025], [0032], claims 9-10). Accordingly, one of ordinary skill in the art prior to the time of the invention would have found it prima facie obvious to combine the art-recognized hyperhidrosis treating compound #5 of Bodor to the hyperhidrosis treating lotion comprising 90% wt. anhydrous ethanol, hydroxypropyl cellulose, and polydimethylsiloxane polymer coated hydrophobic silica of Whipple. Motivation to combine the hyperhidrosis treating compound of Bodor to the hyperhidrosis treating lotion of Whipple flows logically from the very fact each agent was known in the prior art to have the same therapeutic utility of treating hyperhidrosis by topical application in ethanol-based lotions, which in turn, raises the reasonable expectation of success, that when combined, a composition comprising 90% wt. anhydrous ethanol, hydroxypropyl cellulose, polydimethylsiloxane polymer hydrophobic silica and compound #5 of Bodor would be efficacious at treating hyperhidrosis. The instant situation is amenable to the type of analysis set forth in In re Kerkhoven, 205 USPQ 1069 (CCPA 1980) wherein the court held that it is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose (MPEP 2144.06). However, the combination of Whipple and Bodor do not explicitly teach the addition of isopropyl myristate to the anti-sweat composition. Bodor ‘861 teaches compounds of Formula (Ia) which reads on the genus of Formula (II) wherein R1 is phenyl and R2 is cyclopentyl and R is C2 alkyl (abstract, col. 1 and col. 23). Bodor ‘861 teaches that said compounds are anti-sweat compounds used to treat hyperhidrosis (col. 8 lines 1-5). Bodor ‘861 formulates said compound in solutions compositions (col. 11 lines 25-50). Bodor ‘861 exemplifies solution compositions comprising compounds of Formula (I) further comprising isopropyl myristate and absolute ethanol (col. 72-73, Examples 30-35). Kawasaki teaches preparation of antiperspirant lotions composed of anhydrous ethanol. As exemplified in Example 416, said antiperspirant lotion comprises 92% absolute ethanol and 2% wt. isopropyl myristate. Therefore, one of ordinary skill in the art prior to the time of the invention would have found it prima facie obvious to combine isopropyl myristate to the anti-sweat lotion of Whipple and Bodor comprising 90% anhydrous alcohol, hydroxypropyl cellulose, silica and compound #5 in view of Bodor ‘861 and Kawasaki. MPEP 2143 provides rationale for a conclusion of obviousness including (A) combining prior art elements according to known methods to obtain predictable results; In the instant case, the prior art element of formulating the compounds of Formula (II) with isopropyl myristate with established in the methodology of Bodor ‘861 coupled with the knowledge that it was routine in the art to incorporate isopropyl myristate into antiperspirant lotions comprising 90%wt. ethanol in view of Kawasaki. Accordingly, a skilled artisan would have predicted, with a reasonable expectation of success that topical application of a lotion comprising 90% anhydrous ethanol, hydroxypropyl cellulose, silica, isopropyl myristate and compound #5 would have effectively treated hyperhidrosis in the administered subject. Secondly, said artisan would have found it prima facie obvious to treat hyperhidrosis in a subject in need comprising administering the hyperhidrosis composition of Whipple, Bodor, Bodor ‘8611 and Kawasaki to areas in need of sweat reduction, such as the hand-palm area, as Whipple, Bodor, Bodor ‘8611 and Kawasaki teach that topical compositions comprising a compound of Formula (II), at least 90% wt. ethanol, isopropyl myristate and hydroxypropyl methylcellulose are suitable compositions to apply to the hand-palm area to treat hyperhidrosis in the afflicted subject. Lastly, regarding the limitation wherein the composition has greater storage stability compared to a composition comprising an aqueous solvent or aqueous buffer with the proviso that said ingredients are present in amounts such that the product of any transesterification is the same as the compound of Formula (II), Applicant is reminded that properties, such as storage stability are considered characteristic features of the claimed composition. It is noted that MPEP 2112, In re Best (195 USPQ 430) and In re Fitzgerald (205 USPQ 594) discuss the support of rejections wherein the prior art discloses subject matter which there is reason to believe inherently includes functions that are newly cited or is identical to a product instantly claimed. In such a situation the burden is shifted to the applicants to "prove that subject matter shown to be in the prior art does not possess characteristic relied on" (205 USPQ 594, second column, first full paragraph). In the present case, in order to overcome the rejection of record, the burden is shifted to Applicant to prove that the anti-sweat lotion comprising 90% wt. anhydrous ethanol, hydroxypropyl cellulose, isopropyl myristate polydimethylsiloxane polymer hydrophobic silica and compound #5 of Whipple, Bodor, Bodor ‘861 and Kawasaki does not comprise a greater storage stability to a composition comprising an aqueous solvent or aqueous buffer. Claims 16-18, 24-26 are rejected under 35 U.S.C. 103 as being unpatentable over the combination of Whipple (US Patent 6,319,491 published 11/20/2001) Bodor et al (US2014/0275204 published 09/18/2014), Bodor (US Patent 7,399,861 published 07/15/2008, referred to as Bodor ‘861) and Kawasaki (JP2003-113392 published 04/18/2003) as applied to claims 1-15, 19-23 above in view of Williams (GB 2,280,111 published 01/25/1995). As discussed above, the combination of Whipple, Bodor, Bodor ‘861 and Kawasaki render obvious the preparation of an anti-sweat lotion comprising 90% wt. anhydrous ethanol, hydrophobic silica comprising dimethicone (polydimethylsiloxane polymer), decamethylcyclopentasiloxane (cyclomethicone) hydroxypropyl cellulose, isopropyl myristate and compound #5 in order to treat hyperhidrosis. Additionally, the combination of Whipple, Bodor, Bodor ‘861 and Kawasaki render obvious the treatment of hyperhidrosis in a subject in need comprising topical administration of said anti-sweat lotion to areas of the skin that are in need of treating, such as the hand-palm area. However the combination of Whipple, Bodor, Bodor ‘861 and Kawasaki do not specifically teach incorporating hexylene glycol and citric acid into the antiperspirant composition. Williams (GB 2,280,111 published 01/25/1995) teaches anti-perspirant gel compositions comprising a dihydridic alcohol as a primary solvent, buffering agents and gelling agents (abstract). Williams teaches that a buffering agent is used in the composition to prevent wide pH swings, maintaining a pH to about 5 (page 6 lines 2 to page 7 line 10). Citric acid taught as a preferred buffering solution (claims 1, 17-20). Williams also teaches that hexylene glycol is a suitable dihydridic alcohol for the anti-perspirant gel composition (page 4 lines 15-30, claims 1, 6). Williams further teaches administration of said gel composition in order to reduce perspiration on the skin of a mammal in need (claim 26). Therefore, one of ordinary skill in the art prior to the time of the invention would have found it prima facie obvious to combine hexylene glycol and citric acid to the anti-sweat lotion of Whipple, Bodor, Bodor ‘861 and Kawasaki in order to arrive at the instantly claimed antiperspirant composition. MPEP 2143 provides rationale for a conclusion of obviousness including (A) combining prior art elements according to known methods to obtain predictable results; In the instant case, the prior art element of formulating antiperspirant compositions with hexylene glycol and citric acid was established in the methodology of Williams. Accordingly, a skilled artisan would have predicted, with a reasonable expectation of success that topical application of a lotion comprising 90% anhydrous ethanol, hydroxypropyl cellulose, silica, isopropyl myristate, hexylene glycol, citric acid and compound #5 would have effectively treated hyperhidrosis in the administered subject. Furthermore, said artisan would have found it prima facie obvious to treat hyperhidrosis in a subject in need comprising administering the hyperhidrosis composition of Whipple, Bodor, Bodor ‘861, Kawasaki and Williams to areas in need of sweat reduction, such as the hand-palm area, as the combination of Whipple, Bodor, Bodor ‘861, Kawasaki and Williams teach that topical compositions comprising a compound of Formula (II), at least 90% wt. ethanol, isopropyl myristate, hexylene glycol, citric acid and hydroxypropyl methylcellulose are suitable components to formulate together to yield a topical gel composition suitable at reducing perspiration in a subject in need and effective when applied to the hand-palm area. Accordingly, a skilled artisan would have predicted, with a reasonable expectation of success that administration topical composition comprising 90% anhydrous ethanol, hydroxypropyl cellulose, silica, isopropyl myristate, hexylene glycol, citric acid and compound #5 would have effectively treated hyperhidrosis at the administered location of the afflicted subject. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 11,034,652. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-9 of U.S. Patent 11,034,652 are directed to a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol, citric acid, hexylene glycol and hydroxypropyl cellulose. Said topical gel formulation overlaps with the topical gel formulation of Formula (Ia) embraced within claims 1-19 of the present claims. Furthermore, the methodology of treating hyperhidrosis comprising topically administering a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol, citric acid, hexylene glycol and hydroxypropyl cellulose embodied within claims 11-20 of U.S. Patent 11,034,652 overlaps with the treatment methodology embraced within claims 20-26 of the present application. Claims 1-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-29 of U.S. Patent No. 11,052,067. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-14 of U.S. Patent No. 11,052,067 are directed to a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol, citric acid, isopropyl myristate, hexylene glycol and hydroxypropyl cellulose. Said topical gel formulation overlaps with the topical gel formulation of Formula (Ia) embraced within claims 1-19 of the present claims. Furthermore, the methodology of treating hyperhidrosis comprising topically administering a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol, citric acid, hexylene glycol and hydroxypropyl cellulose embodied within claims 15-29 of U.S. Patent 11,052,067 overlaps with the treatment methodology embraced within claims 19-26 of the present application. Claims 1-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-19 of U.S. Patent No. 11,084,788. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-10 of U.S. Patent No. 11,084,788. are directed to a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol, citric acid, hexylene glycol and hydroxypropyl cellulose. Said topical gel formulation overlaps with the topical gel formulation of Formula (Ia) embraced within claims 1-18 of the present claims. Furthermore, the methodology of treating hyperhidrosis comprising topically administering a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol, citric acid, hexylene glycol and hydroxypropyl cellulose embodied within claims 11-19 of U.S. Patent 11,084,788 overlaps with the treatment methodology embraced within claims 19-26 of the present application. Claims 1-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 11,123,325. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-15 of U.S. Patent No. 11,123,325 are directed to a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol, isopropyl myristate, citric acid, hexylene glycol and dimethicone. Said topical gel formulation overlaps with the topical gel formulation embraced within claims 1-19 of the present claims. Furthermore, claims 16-17 of U.S. Patent 11,123,325 are directed to treating hyperhidrosis in a subject in need comprising administering a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol, isopropyl myristate, citric acid, hexylene glycol, hydroxypropyl cellulose and dimethicone. Said methodology and topical formulation overlaps with the methodology and topical formulation embraced within claims 20-26 of the present claims. Claims 20-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 10,947,192. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-10 of U.S. Patent No. 10,947,192 are directed to treating hyperhidrosis in a subject in need comprising administering a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol, and further comprising citric acid, hexylene glycol and the viscosity controlling hydroxypropyl cellulose. Said treatment methodology and topical gel formulation overlaps with the treatment methodology and topical formulation embraced within claims 20-26 of the present claims. Claims 20-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9, 11, 14-15 of U.S. Patent No. 10,959,983. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-9, 11, 14-15 of U.S. Patent No. 10,959,983 are directed to treating hyperhidrosis in a subject in need comprising administering a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol and further comprising isopropyl myristate, citric acid, hexylene glycol and the viscosity controlling hydroxypropyl cellulose. Said treatment methodology and topical gel formulation overlaps with the methodology and topical formulation embraced within claims 20-26 of the present claims. Claims 20-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6, 9, 11-16 and 19 of U.S. Patent No. 10,961,191. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-6, 9, 11-16 and 19 of U.S. Patent No.10,961,191 are directed to treating hyperhidrosis in a subject in need comprising administering a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol and further comprising isopropyl myristate, citric acid, hexylene glycol and the viscosity controlling hydroxypropyl cellulose. Said treatment methodology and topical gel formulation overlaps with the methodology and topical formulation embraced within claims 20-26 of the present claims. Claims 1-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 12,165,865. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-15 of U.S. Patent No. 12,165,865 are directed to a topical formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol and further comprising isopropyl myristate, citric acid, hexylene glycol. Said topical formulation includes a gel, cream, lotion, foam or emulsion as found in claims 6-7 of the present claims. Furthermore, claims 16-22 of U.S. Patent 11,123,325 are directed to treating hyperhidrosis in a subject in need comprising administering a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol and further comprising isopropyl myristate, citric acid, hexylene glycol and hydroxypropyl cellulose. Said treatment methodology and topical formulation overlaps with the methodology and topical formulation embraced within claims 20-26 of the present claims. Claims 1-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9, 12-41 of U.S. Patent No. 12,398,102 Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-9 of U.S. Patent No. 12,398,102 are directed to a topical formulation of a compound of Formula (2a) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol and further comprising isopropyl myristate, citric acid, hexylene glycol and the viscosity controlling modified cellulose. Said topical gel formulation further excludes propyl gallate, butylated hydroxytoluene and the aluminum species aluminum chloride or aluminum chlorohydrate. Said topical gel formulation overlaps with the topical gel formulation of Formula (Ia) embraced within claims 1-19 of the present claims. Furthermore, claims 12-41 of U.S. Patent 12,398,102 are directed to treating hyperhidrosis in a subject in need comprising administering a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol and further comprising isopropyl myristate, citric acid, hexylene glycol and the viscosity controlling modified cellulose and further excludes propyl gallate, butylated hydroxytoluene and the aluminum species aluminum chloride or aluminum chlorohydrate. Said treatment methodology and topical formulation overlaps with the methodology and topical formulation embraced within claims 20-26 of the present claims. Claims 1-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-6, 9-19 of U.S. Patent No. 12,357,609 Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-6, 9-10 and 19 of U.S. Patent No.12,357,609 are directed to a topical formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol and further comprising isopropyl myristate, citric acid, hexylene glycol and the viscosity controlling hydroxypropyl cellulose. Said topical gel formulation further excludes propyl gallate, butylated hydroxytoluene and the aluminum species aluminum chloride or aluminum chlorohydrate. Said topical gel formulation overlaps with the topical gel formulation of Formula (Ia) embraced within claims 1-19 of the present claims. Furthermore, claims 13-18 of U.S. Patent 12,357,609 are directed to treating hyperhidrosis in a subject in need comprising administering a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol and further comprising isopropyl myristate, citric acid, hexylene glycol and the viscosity controlling hydroxypropyl cellulose and further excludes propyl gallate, butylated hydroxytoluene and the aluminum species aluminum chloride or aluminum chlorohydrate. Said treatment methodology and topical formulation overlaps with the methodology and topical formulation embraced within claims 20-26 of the present claims. Claims 1-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5, 8, 11-15 of U.S. Patent No. 11,026,919. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-5 and 8 of U.S. Patent No. 11,026,919 are directed to a topical formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol and further comprising isopropyl myristate, citric acid, hexylene glycol and the viscosity controlling hydroxypropyl cellulose. Said topical gel formulation overlaps with the topical gel formulation of Formula (Ia) embraced within claims 1-19 of the present claims. Furthermore, claims 11-15 of U.S. Patent 11,026,919 are directed to treating hyperhidrosis in a subject in need comprising administering a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol and further comprising isopropyl myristate, citric acid, hexylene glycol and the viscosity controlling hydroxypropyl cellulose. Said treatment methodology and topical formulation overlaps with the methodology and topical formulation embraced within claims 20-26 of the present claims. Claims 20-26 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5, 8-12 of U.S. Patent No. 10,952,990. Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-5, 8-12 of U.S. Patent 10,952,990 are directed to treating hyperhidrosis in a subject in need comprising administering a topical gel formulation of a compound of Formula (2) in 1%wt. to 20% wt., at least 70% wt. anhydrous ethanol and further comprising isopropyl myristate, citric acid, hexylene glycol and the viscosity controlling hydroxypropyl cellulose. Said treatment methodology and topical formulation overlaps with the methodology and topical formulation embraced within claims 20-26 of the present claims. Conclusion In view of the rejections set forth above, no claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to GEORGE W KOSTURKO whose telephone number is (571)270-5903. The examiner can normally be reached M-F 9:00-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, CLINTON A BROOKS can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /GEORGE W KOSTURKO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Oct 18, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §103, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773412
GANAXOLONE FOR USE IN TREATMENT OF SUPER REFRACTORY STATUS EPILEPTICUS
3y 5m to grant Granted Oct 27, 2026
Patent 12766120
COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT
3y 10m to grant Granted Oct 20, 2026
Patent 12766119
METHODS OF TREATING SEIZURE DISORDERS AND PRADER-WILLI SYNDROME
2y 8m to grant Granted Oct 20, 2026
Patent 12767655
Cathinone Derivatives, Pharmaceutical Formulations, and Methods
2y 8m to grant Granted Oct 20, 2026
Patent 12758546
SUSPENSION OF TRIAZOLE ANTIFUNGAL DRUG FOR ATOMIZER
3y 8m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
55%
Grant Probability
99%
With Interview (+48.9%)
Low
PTA Risk
Based on 736 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month